Mineral composition of UFC, B, and SF. by Junxia Zhou (14381598)

Subjects:

Characteristics of patients with abnormal lung function whose severity classification changed when the <i>z</i>-score guidelines from 2022 were applied in comparison to those who w... by Piotr W. Boros (21446186)

Hazard ratios (HR) for all-cause mortality with 95% confidence intervals from Cox regression models using the 2005 vs. the 2022 guidelines for grading severity, normal FVC (<i>n</i... by Piotr W. Boros (21446186)

CSB elemental content. by Shiqi Zhang (709298)

Subjects:

Changes in rumen fluid metabolites. by Shiqi Zhang (709298)

Subjects:

Rumen fermentation parameters. by Shiqi Zhang (709298)

Subjects:

Rumen microflora gene primer information. by Shiqi Zhang (709298)

Subjects:

Feed nutrient disappearance rate. by Shiqi Zhang (709298)

Subjects:

Rumen bacterial and archaeal diversity. by Shiqi Zhang (709298)

Subjects:

Key significant pathways in the final models of self-compassion. by Eriko Takahashi (22608061)

Subjects:

Fig 5 - by Yong-Rae Kim (19797278)

Subjects:

Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Exclusion and enrollment summary from NHANES. by Lu Han (151620)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: